血小板相关抗体在儿童免疫性血小板减少症治疗效果评估中的临床价值

doi:10.3969/j.issn.1006-6233.2024.01.015

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1194 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical value of platelet associated antibodies (PA-Ig) in evaluating the therapeutic effect on children with immune thrombocytopenia (ITP). Methods: A study from February 2020 to February 2023 was conducted. 104 children with ITP (observation group) and 22 healthy children (control group) were selected as the study subjects. Children in the observation group were divided into the complete response group, the effective group, and the ineffective group based on the treatment outcomes. All children were tested for PA-Ig levels. Results: Among the 104 children in the observation group, 85 (81.73%) achieved complete response (complete response group), 11 (10.58%) showed effectiveness (effective group), and the remaining 8 (7.69%) were ineffective (ineffective group). PA-IgG, PA-IgM, and PA-IgA levels in the observation group were lower than those in the control group (P<0.05). In the complete response group, PA-IgG, PA-IgM, and PA-IgA levels were lower than in the effective and ineffective groups. The effective group had lower levels compared to the ineffective group. There were statistically significant differences in PA-IgG, PA-IgM, and PA-IgA levels among the three groups with different treatment outcomes (P<0.05). Conclusion: Testing PA-Ig levels in pediatric ITP patients is beneficial for tailoring treatment and assessing early efficacy, reducing the risk of treatment, and has certain value in the evaluation of treatment outcomes in pediatric ITP patients.

Key words： Immune thrombocytopenia Platelet associated antibody Child Therapeutic effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.01.015 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I1/80

[1] Al-Samkari H,Jiang D,Gernsheimer T,et al.Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim:a multicentre US study[J].Br Haematol,2022,197(3):359-366.
[2] 祁闪闪,杨李,宋娜,等.免疫性血小板减少症患儿外周血Treg细胞GITR表达及临床意义[J].中国免疫学杂志,2023,39(3):595-598,605.
[3] 王亚敏.重组人血小板生成素联合大剂量地塞米松治疗重症免疫性血小板减少症的临床效果[J].临床合理用药杂志,2022,15(29):96-99.
[4] 中华医学会儿科学分会血液学组,《中华儿科杂志》编辑委员会.儿童原发性免疫性血小板减少症诊疗建议[J].中华儿科杂志,2013,51(5):382-384.
[5] Cooper N,Kruse A,Kruse C,et al.Immune thrombocytopenia (ITP) World Impact Survey (I-WISh):Impact of ITP on health-related quality of life[J].Am Hemato,2021,96(2):199-207.
[6] 张雅丽,闫雪峰,冯茹清,等.EBV通过抑制IFN-α蛋白表达逃逸免疫应答促进免疫性血小板减少症发生的机制[J].临床误诊误治,2023,36(3):139-142,152.
[7] 朱筱旌,马静瑶,陈振萍,等.小剂量利妥昔单抗二线治疗儿童原发性免疫性血小板减少症90例临床观察[J].中国小儿血液与肿瘤杂志,2022,27(6):367-371,389.
[8] 张婷,智艳芳,荣守华.MPV、PDW、P-LCR与ITP患儿病情严重程度的相关性分析[J].保健医学研究与实践,2022,19(2):63-65.
[9] 郭晶晶,潘素贞,汤呈珏,等.儿童免疫性血小板减少症的影响因素研究[J].中国卫生检验杂志,2021,31(16):2018-2021.
[10] 焦阿金,何川疆,许爱敏.血小板相关抗体在维吾尔族免疫性血小板减少性紫癜诊断中的应用价值分析[J].国际检验医学杂志,2020,41(4):481-483.
[11] 武莉芳,陈兰英,李芳,等.白细胞介素及血小板相关抗体在IPT患者中的表达意义[J].河北医学,2018,24(4):692-694.